A humanized anti-cocaine mAb blocks the cardiovascular effects of cocaine in rats

被引:0
|
作者
Koch, Sheryl E.
Marckel, Jordan
Rubinstein, Jack
Norman, Andrew B.
机构
[1] Div of Cardiovascular Health & Disease, University of Cincinnati, Cincinnati
[2] Pharmacology & Systems Physiology, University of Cincinnati, Cincinnati
来源
FASEB JOURNAL | 2022年 / 36卷
关键词
D O I
10.1096/fasebj.2022.36.S1.R5356
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cocaine use and abuse is associated with significant morbidity and mortality. Further, its use has significant effects on cardiovascular function in humans and has been associated with development of chest pain, myocardial ischemia and in rare cases cardiac death. Currently, the FDA has no approved pharmacotherapy for cocaine abuse. We have developed and generated a humanized anti-cocaine monoclonal antibody (mAb), h2E2, which dramatically decreases brain cocaine concentrations by sequestering cocaine in the plasma. As h2E2 proceeds into clinical trials, a significant question remains as to whether the increased plasma cocaine concentrations, increased circulation time of cocaine, and the decrease in cocaine excretion into the urine affects cardiac function. Therefore, the objective of this study was to determine the dose, duration and effects of cocaine administration in the presence and absence of mAb h2E2 on echocardiographic variables in an in vivo rat model. Echocardiography was performed on Sprague-Dawley rats with indwelling catheters using the Vevo 2100 ultrasound machine with a 20mHz probe. Baseline echocardiographic long axis M-mode images were collected prior to an i.v. cocaine push and at subsequent time points thereafter. Initial studies determined the dose-dependent effect of cocaine on cardiac parameters including ejection fraction (EF), heart rate (HR) and cardiac output (CO). The most significant increase in EF was observed with 1.68mg/kg cocaineHCl, which was then used in the subsequent experiments. As noted, cocaine administration increased EF, with inversely proportional changes in left ventricular systolic volume. In addition, cocaine produced an immediate decrease in HR, which did not fully return to baseline over the 45 minute time course, likely due to the anesthesia, as the saline control group demonstrated comparable effects. Similarly, cocaine caused an immediate decrease in CO, which normalized over time. Pre-administration of a single equimolar dose of h2E2 significantly blunted the effect of cocaine on EF, including both the initial drop as well as the subsequent increase. At one week and one month post h2E2, there was no significant blunting of the increased in cocaine-induced inotropy. However, the initial decrease in EF was still blocked after one week. The initial cocaine-induced drop in HR was blocked by h2E2, even at 1 week post-injection. h2E2 similarly blocked the increase in CO, however this effect was not detectable after 1 week or 1 month. In conclusion, there were no significant adverse cardiac effects noted with h2E2 administration and co-administration with cocaine resulted in significant blunting of both cocaine's inotropic and chronotropic effects. Elevated plasma cocaine concentrations are pharmacologically inert in the presence of h2E2. © FASEB.
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Assessment of Anti-Cocaine Vaccine dAdGNE in Clinical Cohort 1 of Cocaine Addicts
    Kaminsky, Stephen M.
    Beeder, Ann B.
    Salvatore, Mirella
    Cram, Sara
    Lee, Hyunmi
    Xu, Fang
    Jackson, Katie
    Vako, Lorena
    De, Bishnu P.
    Mancenido, Denesy
    Sondhi, Dolan
    Crystal, Ronald G.
    Pagovich, Odelya E.
    MOLECULAR THERAPY, 2019, 27 (04) : 301 - 301
  • [42] Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice
    Brimijoin, Stephen
    Orson, Frank
    Kosten, Thomas R.
    Kinsey, Berma
    Shen, Xiao Yun
    White, Sarah J.
    Gao, Yang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2013, 203 (01) : 212 - 216
  • [43] Immunization with an Adenovirus-Cocaine Conjugate Induces Anti-Cocaine Humoral Immunity
    Alsaied, Osama
    Boyer, Julie L.
    De, Bishnu P.
    Moreno, Amira Y.
    Janda, Kim
    Worgall, Stefan
    Crystal, Ronald G.
    MOLECULAR THERAPY, 2009, 17 : S378 - S379
  • [44] The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice (vol 31, pg 387, 2014)
    Wetzel, Hanna N.
    Tabet, Michael R.
    Ball, William J.
    Norman, Andrew B.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 272 - 273
  • [45] FRAMING AND DOSAGE EFFECTS: EXAMINING EFFICACY OF ANTI-COCAINE VISUAL MESSAGES
    Banerjee, Smita
    Greene, Kathryn
    ANNALS OF BEHAVIORAL MEDICINE, 2011, 41 : S46 - S46
  • [46] Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage
    Gao, Yang
    Geng, Liyi
    Orson, Frank
    Kinsey, Berma
    Kosten, Thomas R.
    Shen, Xiaoyun
    Brimijoin, Stephen
    CHEMICO-BIOLOGICAL INTERACTIONS, 2013, 203 (01) : 208 - 211
  • [47] Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion
    Carroll, Marilyn E.
    Zlebnik, Natalie E.
    Anker, Justin J.
    Kosten, Thomas R.
    Orson, Frank M.
    Shen, Xiaoyun
    Kinsey, Berma
    Parks, Robin J.
    Gao, Yang
    Brimijoin, Stephen
    PLOS ONE, 2012, 7 (08):
  • [48] Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model
    Kantak, KN
    Collins, SL
    Lipman, EG
    Bond, J
    Giovanoni, K
    Fox, BS
    PSYCHOPHARMACOLOGY, 2000, 148 (03) : 251 - 262
  • [49] Computational design of an enzyme mutant for anti-cocaine medication
    Gao, Daquan
    Yang, Wenchao
    Yang, Yongmei
    Tai, Hsin-Hsiung
    Zhan, Chang-Guo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [50] Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model
    K. M. Kantak
    S. L. Collins
    E. G. Lipman
    J. Bond
    K. Giovanoni
    B. S. Fox
    Psychopharmacology, 2000, 148 : 251 - 262